Evidence record · ER-IPAMORELIN-RECOVERY-008
Does ipamorelin improve recovery or body composition?
Ipamorelin improves recovery, muscle gain or body composition
Ipamorelin has not been shown in dependable human trials to improve recovery, muscle gain or body composition. Evidence that it can release growth hormone acutely does not establish a patient-important or performance benefit. Long-term effects, uncommon harms and the equivalence of products sold online remain unresolved.
Claim boundary
What this verdict covers
The claim requires direct measures of recovery, function, lean mass or fat mass over useful follow-up. A short-lived hormone response does not meet that outcome definition.
- Compound
- Ipamorelin
- Population
- Adults seeking recovery or physique change
- Outcome
- Recovery, lean mass, fat mass or function
- Record ID
- ER-IPAMORELIN-RECOVERY-008
Evidence synthesis
What the research can support
Human ipamorelin research has mainly addressed pharmacology or specific development programmes rather than recovery and physique claims. No suitable independently replicated body-composition or injury-recovery programme was identified.
Why the confidence is very low
The evidence is indirect, follow-up is inadequate for chronic use and endocrine surrogate changes cannot quantify net benefit or harm.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-IPAMORELIN-RECOVERY-008 addresses one bounded question: Does ipamorelin improve recovery or body composition?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is No reliable evidence, the verdict is Insufficient and confidence is Very low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Human ipamorelin pharmacology study | The study supports an acute hormone-release effect. | It does not establish recovery or body-composition benefit. | 10 August 2026 |
| Ipamorelin clinical-development study | The study provides human exposure in a defined clinical programme. | It does not support general muscle, fat-loss or recovery claims. | 10 August 2026 |
| FDA bulk-substance safety page | FDA identifies important safety-information gaps for ipamorelin. | It does not determine the contents of an online vial. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Ipamorelin for this claim?
The verdict is insufficient for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Human ipamorelin research has mainly addressed pharmacology or specific development programmes rather than recovery and physique claims. No suitable independently replicated body-composition or injury-recovery programme was identified. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Ipamorelin authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Growth hormone secretagogues, including ipamorelin, are prohibited at all times under the WADA S2 category. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
A randomised trial of a characterised product that measures recovery or body composition directly and reports functional outcomes and longer-term adverse events. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation